Clinical Trials Logo

Clinical Trial Summary

Autoimmunity is the main cause of diabetes type 1 and an important factor as cause of Latent Autoimmune Diabetes in Adults (LADA). Recently, research has found that being deficient of T-reg cells is an important cause of autoimmunity. The study hypothesis are:

1. Patients with newly found diabetes type 1 have less T-reg than healthy.

2. Patients with newly found diabetes type 1 have less T-reg than patients with long duration of the illness.

3. The number of T-reg is negative associated with HLA-risk-haplotype.

4. The number of T-reg is negative associated with LADA.

5. Differences relating to inflammatory cytokines will be seen among patients with newly found diabetes type 1, but not among others.


Clinical Trial Description

Research has worked out that b-cells are being destroyed by cytokines released from inflammatory cells. One hypothesis in that T-reg is a cause of autoimmunity, and that T-reg concentrations are low in patients with newly diagnosed diabetes type 1.

Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes, Latent Autoimmune Diabetes in Adults (LADA) and type 1 diabetes older than 10 years and the same amount of samples from healthy, age- and sex-matched blood donors. Markers of autoimmune diabetes will be analyzed. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01148238
Study type Observational
Source Norwegian University of Science and Technology
Contact
Status Withdrawn
Phase N/A
Start date August 2012
Completion date December 2012

See also
  Status Clinical Trial Phase
Completed NCT03618420 - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function Phase 1/Phase 2
Recruiting NCT05866536 - Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years Phase 2
Not yet recruiting NCT04698330 - Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA Phase 4
Recruiting NCT05319990 - Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)
Completed NCT04793165 - Is the Artificial Pancreas, Without Carbohydrate Counting, Efficient and Safe in an Outpatient Setting N/A
Completed NCT05168657 - Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth N/A
Recruiting NCT05180591 - Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes Phase 2
Recruiting NCT01559025 - Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus Phase 3
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Active, not recruiting NCT02081326 - Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes Phase 2
Completed NCT01881009 - Medtronic Minimed Overnight Closed-Loop System N/A
Recruiting NCT03011008 - Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus Phase 4
Recruiting NCT03011021 - Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes Phase 1/Phase 2
Completed NCT04074668 - Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance
Terminated NCT00837759 - Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes Phase 2
Completed NCT03345004 - Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes Phase 2
Active, not recruiting NCT03945747 - MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus
Recruiting NCT03513874 - Metformin Plus Insulin on Non-obese Autoimmune Diabetes Phase 4
Enrolling by invitation NCT04335513 - Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D N/A